Divergent effects of Abeta1-42 on ionotropic glutamate receptor-mediated responses in CA1 neurons in vivo - PubMed (original) (raw)
Comparative Study
. 2005 Nov 16;1062(1-2):120-6.
doi: 10.1016/j.brainres.2005.09.014. Epub 2005 Oct 24.
Affiliations
- PMID: 16248989
- DOI: 10.1016/j.brainres.2005.09.014
Comparative Study
Divergent effects of Abeta1-42 on ionotropic glutamate receptor-mediated responses in CA1 neurons in vivo
Viktor Szegedi et al. Brain Res. 2005.
Abstract
Aggregated Abeta1-42 is hypothesized to be the central cause of Alzheimer's disease. However, early changes in synaptic activity may be detected in the disease long before a significant cell loss is manifested. Despite the fact that Abeta1-42 interference with long-term potentiation (LTP) and the field excitatory postsynaptic potential (fEPSP) is well documented, the exact mechanism of these events remains to be clarified. Here we studied the effects of iontophoretically applied Abeta1-42 on the neuronal firing evoked in vivo on the CA1 hippocampal neurons of Wistar rats by different agonists of the ionotropic glutamate receptors: N-methyl-d-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainic acid (KA). NMDA elicited firing enhanced in all of the measured cells; in contrast, the AMPA-mediated responses decreased significantly after Abeta1-42 ejection. The changes in KA-evoked responses to Abeta1-42 revealed two types of cells. In the first type, the KA-mediated firing remained at the control level, while in the second type, Abeta1-42 attenuated the KA-evoked responses. A protective pentapeptide, Leu-Pro-Tyr-Phe-Asp-amide, was used to verify the specificity of these beta-amyloid-elicited effects. The pentapeptide protected against the modulatory effects of Abeta1-42 on the NMDA and AMPA responses. In conclusion, we have shown that Abeta1-42 exerts divergent effects on the activity of the ionotropic glutamate receptors in vivo. These results suggest that the LTP disruption and fEPSP attenuation seen after Abeta1-42 application are in part due to the altered function of these receptors.
Similar articles
- N-methyl-D-aspartate receptor-dependent long-term potentiation in CA1 region affects synaptic expression of glutamate receptor subunits and associated proteins in the whole hippocampus.
Zhong WX, Dong ZF, Tian M, Cao J, Xu L, Luo JH. Zhong WX, et al. Neuroscience. 2006 Sep 1;141(3):1399-413. doi: 10.1016/j.neuroscience.2006.04.070. Epub 2006 Jun 12. Neuroscience. 2006. PMID: 16766131 - The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo.
Schmid AW, Lynch MA, Herron CE. Schmid AW, et al. Hippocampus. 2009 Jul;19(7):670-6. doi: 10.1002/hipo.20542. Hippocampus. 2009. PMID: 19115392 - Pentapeptides derived from Abeta 1-42 protect neurons from the modulatory effect of Abeta fibrils--an in vitro and in vivo electrophysiological study.
Szegedi V, Fülöp L, Farkas T, Rózsa E, Robotka H, Kis Z, Penke Z, Horváth S, Molnár Z, Datki Z, Soós K, Toldi J, Budai D, Zarándi M, Penke B. Szegedi V, et al. Neurobiol Dis. 2005 Apr;18(3):499-508. doi: 10.1016/j.nbd.2004.12.008. Neurobiol Dis. 2005. PMID: 15755677 - NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus.
Yamin G. Yamin G. J Neurosci Res. 2009 Jun;87(8):1729-36. doi: 10.1002/jnr.21998. J Neurosci Res. 2009. PMID: 19170166 Review. - Involvement of glutamate receptors, lipases, and phospholipases in long-term potentiation and neurodegeneration.
Farooqui AA, Horrocks LA. Farooqui AA, et al. J Neurosci Res. 1994 May 1;38(1):6-11. doi: 10.1002/jnr.490380103. J Neurosci Res. 1994. PMID: 8057391 Review.
Cited by
- Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression.
Inoue Y, Ueda M, Masuda T, Misumi Y, Yamashita T, Ando Y. Inoue Y, et al. Mol Neurobiol. 2019 Dec;56(12):8573-8588. doi: 10.1007/s12035-019-01678-7. Epub 2019 Jul 6. Mol Neurobiol. 2019. PMID: 31280448 - Does COVID-19 contribute to development of neurological disease?
Mahalakshmi AM, Ray B, Tuladhar S, Bhat A, Paneyala S, Patteswari D, Sakharkar MK, Hamdan H, Ojcius DM, Bolla SR, Essa MM, Chidambaram SB, Qoronfleh MW. Mahalakshmi AM, et al. Immun Inflamm Dis. 2021 Mar;9(1):48-58. doi: 10.1002/iid3.387. Epub 2020 Dec 17. Immun Inflamm Dis. 2021. PMID: 33332737 Free PMC article. Review. - GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo.
Hu NW, Klyubin I, Anwyl R, Rowan MJ. Hu NW, et al. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20504-9. doi: 10.1073/pnas.0908083106. Epub 2009 Nov 16. Proc Natl Acad Sci U S A. 2009. PMID: 19918059 Free PMC article. - Peripheral and central administration of T3 improved the histological changes, memory and the dentate gyrus electrophysiological activity in an animal model of Alzheimer's disease.
Farbood Y, Shabani S, Sarkaki A, Mard SA, Ahangarpour A, Khorsandi L. Farbood Y, et al. Metab Brain Dis. 2017 Jun;32(3):693-701. doi: 10.1007/s11011-016-9947-2. Epub 2017 Jan 26. Metab Brain Dis. 2017. PMID: 28124751 - The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy.
Peña F, Gutiérrez-Lerma A, Quiroz-Baez R, Arias C. Peña F, et al. Curr Neuropharmacol. 2006 Apr;4(2):149-63. doi: 10.2174/157015906776359531. Curr Neuropharmacol. 2006. PMID: 18615129 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous